Literature DB >> 31177860

Tracking the price of existing biologics when drugs enter the market.

Katherine M Stiff1, Abigail Cline1, Steven R Feldman1,2,3,4.   

Abstract

Keywords:  Biologics; biosimilars; cost; drugs; market

Mesh：

Substances：

Year:  2019        PMID： 31177860     DOI： 10.1080/14737167.2019.1630274

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN： 1473-7167            Impact factor:   2.217


× No keyword cloud information.
  3 in total

1.  Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria.

Authors:  Konstantin Tachkov; Zornitsa Mitkova; Vladimira Boyadzieva; Guenka Petrova
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-14

2.  Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC).

Authors:  Konstantinos Syrigos; Istvan Abert; Zoran Andric; Igor N Bondarenko; Mikhail Dvorkin; Kristina Galic; Rinat Galiulin; Vladimer Kuchava; Virote Sriuranpong; Dmytro Trukhin; Edvard Zhavrid; Dongyue Fu; Laurent M Kassalow; Stephanie Jones; Zahid Bashir
Journal:  BioDrugs       Date:  2021-07-15       Impact factor: 5.807

3.  Equivalence and switching between biosimilars and reference molecules in rheumatoid arthritis: protocol for a systematic review and meta-analysis.

Authors:  Bruna O Ascef; Matheus O Almeida; Ana Cristina de Medeiros Ribeiro; Danieli C O Andrade; Haliton A de Oliveira Júnior; Tiago V Pereira; Patrícia C de Soárez
Journal:  Syst Rev       Date:  2021-07-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.